Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology

Colorectal With Associated Risk Factors Clinical Trial

— DParcoursDig  

Official title:

Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology - DISSPO Parcours Dig' Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04478175
• Other study ID #: IC 2020-01
• Status: Completed
• Phase: N/A
• Start date: April 29, 2021
• Est. completion date: October 5, 2022

Study information

• Verified date: November 2022
• Source: Institut Curie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with advanced gastrointestinal (GI) cancers are very often sarcopenic/malnourished at diagnosis (> 60% of cases) and at high risk of rapid clinical deterioration. These patients have important supportive care needs that represent a major challenge for improving treatment tolerance and patient survival and health-related quality of life (HRQoL). Malnutrition and sarcopenia (muscle wasting and dysfunction) are associated with an increased risk of death, complications from chemotherapy, infections, emergency procedures and hospitalizations, and increased costs of care. Therefore, malnutrition and sarcopenia represent a major clinical target in GI cancers. Interventions targeting malnutrition/sarcopenia should be implemented as early as possible in patients' pathways, these syndromes being reversible at early stages but not at late stages. A multidisciplinary assessment at diagnosis and therapeutic approach combining nutritional support and and adapted physical activity (APA) in addition to anticancer treatments should be systematically implemented in patients with advanced GI cancers. This type of intervention complies with the standards recommended by the National Cancer Institute (INCa) to promote the practice of physical activity during and after treatment in oncology.

Description:

All patients will receive usual care including: - Chemotherapy at the investigator's choice, - Outpatient clinical visits according to the regular schedule, - Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks. Nutritional support will consist of: - A nutrition assessment by a dietician including a VAS of food intakes at baseline, at W4 and W8 (plus additional visits if required), - Nutritional intervention according to the Société Francophone de Nutrition Clinique et Métabolisme (SFNEP) guidelines (dietetic counseling for all patients ± oral supplementation, enteral tube feeding, and/or parenteral nutrition). Physical activity support will consist of physical condition assessed by International Physical Activity Questionnaire (IPAQ), performance status (ECOG PS), resting heart rate and blood pressure, 6-minute walking test (speed, fatigue), handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 5, 2022
• Est. primary completion date: October 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent,

2. Age = 18 years (no superior limit),

3. Histologically confirmed (1) non-colorectal cancer (esophagus, stomach, liver/bile ducts, pancreas, neuroendocrine carcinoma) or (2) colorectal with associated risk factors i.e. ECOG PS 2 (defining significant limitation in daily activities), and/or weight loss = 5% in 1 month or = 10% in 6 months (defining malnutrition/HAS 2019),

4. Advanced disease not amenable to surgery, radiation, or combined modality therapy with curative intent (previous resection of primary tumor allowed), treated with first-line chemotherapy for advanced disease (previous [neo]adjuvant chemo[radio]therapy allowed); or resectable/potentially resectable disease receiving a triplet chemotherapy regimen in a peri-operative setting (e.g. FOLFIRINOX, FLOT) (moderate risk at frailty score)

5. Patients able to attend for administration of chemotherapy,

6. Life expectancy = 3 months,

7. Registration in a National Health Care System (Couverture Maladie Universelle [CMU] included).

Exclusion Criteria:

1. Other active non gastro-intestinal cancers

2. Any medical (including psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice,

3. Pregnancy or breastfeeding,

4. Protected adults (individuals under guardianship by court order). Note: participation to another concomitant clinical trial is allowed, but the patient must inform the Investigator and get an authorization from the Sponsor.

Related Conditions & MeSH terms

• Carcinoma, Neuroendocrine
• Colorectal With Associated Risk Factors
• Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma)

Intervention

Other:
• multidisciplinary assessment and intervention
early multidisciplinary assessment and intervention in addition to usual patient care

Locations

Country	Name	City	State
France	Institut Curie	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Institut Curie

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Program faisability	Program feasibility will be satisfactory if = 80% of patients with advanced GI cancers included in the program complete the baseline, W4 and W8 assessments	12 months
Secondary	Dimensions of EORTC QLQ-C30	EORTC QLQ-C30 completion	12 months
Secondary	Fatigue measured by Visual Analogue Scale (VAS)	Visual Analogue Scale (VAS) completion, a score form 0 to 10 will be given	12 months
Secondary	Pain measured by VAS and analgesics consumption	VAS completion and analgesics consumption report, a score form 0 to 10 will be given and report of analgesics consumption will be given by name and dose	12 months
Secondary	Nutritional status/inflammation measure	weight in kilograms, body mass index will be reported in BMI in kg/m^2, food intakes	12 months
Secondary	Physical condition assessed	International Physical Activity Questionnaire (IPAQ),	12 months
Secondary	Geriatric assessment if age = 70	G8 score from 0 to 17	12 months
Secondary	Chemotherapy tolerance assessed	toxicities (using Common Terminology Criteria for Adverse Events [CTCAE v5.0])	12 months
Secondary	Progression Free Survival and Overall Survival	Progression Free Survival and Overall Survival	12 months
Secondary	Patient's satisfaction measured by VAS	VAS completion with a score from 0 to 10	12 months